Eine Studie zu Vemurafenib und Obinutuzumab im Vergleich zu Cladribin und Rituximab bei Menschen mit Haarzell-Leukämie (HCL)
Eine randomisierte, multizentrische Phase-II-Studie zu Vemurafenib plus Obinutuzumab vs. Cladribin plus Rituximab bei Patienten mit zuvor unbehandelter Haarzell-Leukämie (HCL)
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Jae Park, MD
- Telefonnummer: 646-608-3743
- E-Mail: parkj6@mskcc.org
Studieren Sie die Kontaktsicherung
- Name: Mark Geyer, MD
- Telefonnummer: 646-608-3745
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Noch keine Rekrutierung
- Dana Farber Cancer Institute
-
Kontakt:
- Eric Winer, MD
- Telefonnummer: (617) 632-6876
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Noch keine Rekrutierung
- Mayo Clinic Cancer Center
-
Kontakt:
- Sameer Parikh, M.B.B.S.
- Telefonnummer: 507-218-0772
-
-
New Jersey
-
Basking Ridge, New Jersey, Vereinigte Staaten, 07920
- Rekrutierung
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
-
Kontakt:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
Middletown, New Jersey, Vereinigte Staaten, 07748
- Rekrutierung
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Kontakt:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
Montvale, New Jersey, Vereinigte Staaten, 07645
- Rekrutierung
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
Kontakt:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
-
New York
-
Commack, New York, Vereinigte Staaten, 11725
- Rekrutierung
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)
-
Kontakt:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
Harrison, New York, Vereinigte Staaten, 10604
- Rekrutierung
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
Kontakt:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Kontakt:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
Uniondale, New York, Vereinigte Staaten, 11553
- Rekrutierung
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
Kontakt:
- Jae Park, MD
- Telefonnummer: 646-608-3743
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- Ohio State University
-
Kontakt:
- Seema Bhat, MD
- Telefonnummer: 614-293-3196
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patients must be ≥ 18 years of age
-
Histologically confirmed classical HCL by the enrolling institution
-
Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry. If patient is known to have negative BRAF mutation, repeat testing is advisable as well as discussion with the main study principal investigator.
-
Has not received any prior therapy for the disease
-
Patients who meet the standard treatment initiation criteria, as defined by ANC ≤1.0, Hgb ≤ 10.0 or PLT ≤100K
-
ECOG performance status of 0 - 2
-
Acceptable pre-study organ function during screening as defined as:
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except in patients with known Gilbert's syndrome who may be enrolled if direct bilirubin ≤ 3 x ULN);
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; and
- Serum creatinine ≤ 1.5x ULN
-
Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QTc, Bazett's formula) of < 480 msec
-
For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib and cladribine, and 18 months after discontinuation of rituximab and obinutuzumab
-
For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib
-
Negative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potential
Exclusion Criteria:
-
Have had previous treatment for HCL, including purine analogs, vemurafenib, rituximab, obinutuzumab, and other investigational agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed.
-
Known hypersensitivity to any of the study drugs.
-
Patients with known long QT syndrome or uncorrectable electrolyte abnormalities
-
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
-
Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
° Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and take HBV viral prophylaxis such as entecavir.
-
Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)
-
Active uncontrolled infection, e.g. persistent bacteremia, supplemental oxygen or pressor supports, etc.
-
Live vaccination within 28 days of randomization
-
Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years
-
Malabsorption syndrome or other condition that precludes enteral route of administration
-
Patients with HCL variant (as defined by absence of expression of CD25)
-
Pregnant or lactating, or intending to become pregnant during the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Vemurafenib plus Obinutuzumab
Patients assigned to the study arm will receive vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered on days 1, 8 and 15 during the cycle 2 and every 4 weeks during the cycle 3 and 4 of treatment. |
Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. |
|
Aktiver Komparator: Standard treatment of Cladribine plus Rituximab
Patients assigned to the SOC arm will receive cladribine IV on days 1-5 concurrently with rituximab IV per week for 8 times, i.e., weekly x8 from day 1. |
Cladribine IV on days 1-5 concurrently with rituximab. Rituximab on days 1-5 concurrently with rituximab. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
incidences of ≥ grade 3 treatment-related toxicities
Zeitfenster: within 6 months of treatment
|
per CTCAE v5.0 within first 6 months from the start of the treatment to account delayed toxicities of the treatments |
within 6 months of treatment
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
complete remission
Zeitfenster: 2 years
|
Response will be determined by the Consensus Resolution response criteria. Complete response (CR)
|
2 years
|
|
partial response
Zeitfenster: 2 years
|
Partial response (PR) °A normalization of cytopenias °≥50% reduction in organomegaly and bone marrow hairy cells. |
2 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Jae Park, MD, Memorial Sloan Kettering Cancer Center
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Leukämie
- Hämische und lymphatische Krankheiten
- Leukämie, Haarzelle
- Aminosäuren, Peptide und Proteine
- Proteine
- Schwefelverbindungen
- Organische Chemikalien
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Nukleinsäuren, Nukleotide und Nukleoside
- Amides
- Indolen
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Purines
- Nukleoside
- Ribonukleoside
- Antikörper, monoklonale, murine abgeleitete
- Desoxyribonukleoside
- Sulfonamide
- Sulfone
- 2-Chloroadenosin
- Adenosin
- Purin -Nukleoside
- Desoxyadenosinen
- Rituximab
- Vemurafenib
- Cladribin
- Obinutuzumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 24-160
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .